Aurobindo Pharma Ltd - AUROBINDO PHARMA Share Price

Sector: Pharmaceuticals | ISIN: INE406A01037
₹ 611.30 (-0.58%) icon29 May, 2023, 3:57:46 PM
Open
₹ 621.05
Prev. Close
₹ 614.85
Turnover(lac)
₹ 25,734.05
Day's High
₹ 621.05
Day's Low
₹ 584.65
52 Wk High
₹ 648.20
52 Wk Low
₹ 397.20
Book Value
₹ 313.13
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 35,818.43
P/E
24.53
EPS
24.92
Div. Yield
0.00

Aurobindo Pharma Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/29/2023 3:57:46 PM

    ₹ 611.3 -3.55 -0.58
  • Open
  • ₹ 621.05
  • Prev. Close
  • ₹ 614.85
  • Turnover(Lac.)
  • ₹ 25,734
  • Day's High
  • ₹ 621.05
  • Day's Low
  • ₹ 584.65
  • 52 Week's High
  • ₹ 648.2
  • 52 Week's Low
  • ₹ 397.2
  • Book Value
  • ₹ 313.13
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 35,818.43
  • P/E
  • 24.53
  • EPS
  • 24.92
  • Divi. Yield
  • 0

Aurobindo Pharma Ltd Corporate Actions

18 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

09 Feb , 2023

12:00 AM

Dividend

Dividend amount: 3
Announcement date: 09 Feb , 2023

View Details

31 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jan , 2023

12:00 AM

14 Dec , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Oct , 2022

12:00 AM

03 Aug , 2022

12:00 AM

03 Aug , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

07 Jul , 2022

12:00 AM

AGM

Announcement date: 07 Jul , 2022

View Details

18 Jun , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 May , 2022

12:00 AM

Dividend

Dividend amount: 4.5
Announcement date: 30 May , 2022

View Details

20 May , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

07 Jul , 2022

12:00 AM

BookCloser

View Details

Aurobindo Pharma Ltd SHAREHOLDING SNAPSHOT
30 May , 2023 | 12:51 AM

PROMOTER - TOTAL51.83%

Indian: 48.76%

Foreign: 3.072%

NON-PROMOTER - TOTAL 48.17%

Institutions: 38.11%

Non-Institutions: 10.05%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Aurobindo Pharma Ltd News and Update

Image not found
  • 9 hours ago |
  • 5:39 PM

Recommendation: Add; Target Price: Rs 165

Image not found
Image not found
Image not found
  • IIFL News Service |
  • 25 May, 2023 |
  • 5:33 PM
ad IconAd Image

Aurobindo Pharma Ltd FINANCIALS

Aurobindo Pharma Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Aurobindo Pharma Ltd

  • P V Ramprasad Reddy
  • Non-Exec & Non-Independent Dir
  • K Nithyananda Reddy
  • Vice Chairman & M.D.
  • M Sivakumaran
  • Whole-time Director
  • M Madan Mohan Reddy
  • Whole-time Director
  • P Sarath Chandra Reddy
  • Director
  • K Ragunathan
  • Chairman & Independent Directo
  • Avnit Bimal Singh
  • Non-Exec. & Independent Dir.
  • B Adi Reddy
  • Company Secretary
  • Savita Mahajan
  • Non-Exec. & Independent Dir.
  • Girish Paman Vanvari
  • Non-Exec. & Independent Dir.
  • Santanu Mukherjee
  • Independent Director

Summary

Aurobindo Pharma Limited (APL), one of the worlds top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The companys robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindos products. APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins... Read More


Reports by Aurobindo Pharma Ltd


Reports by Aurobindo Pharma Ltd